Disease-Associated Microglia in Alzheimer's Disease

Disease-Associated Microglia in Alzheimer's Disease

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Disease-Associated Microglia in Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Innate Immune Cells</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Brain parenchyma, near amyloid plaques</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Activated microglia</td>
</tr>
<tr>
<td class="label">Key Receptors</td>
<td>TREM2, TLRs, CD33</td>
</tr>
<tr>
<td class="label">Discovery</td>
<td>2019 (Keren-Shaul et al., Cell)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Trigger</td>
<td>Microenvironmental signals (Aβ, neuronal injury)</t

Disease-Associated Microglia in Alzheimer's Disease

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Disease-Associated Microglia in Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Innate Immune Cells</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Brain parenchyma, near amyloid plaques</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Activated microglia</td>
</tr>
<tr>
<td class="label">Key Receptors</td>
<td>TREM2, TLRs, CD33</td>
</tr>
<tr>
<td class="label">Discovery</td>
<td>2019 (Keren-Shaul et al., Cell)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000095](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Trigger</td>
<td>Microenvironmental signals (Aβ, neuronal injury)</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>Downregulation of P2ry12, Cx3cr1</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Initial response, limited phagocytosis</td>
</tr>
<tr>
<td class="label">TREM2 Status</td>
<td>TREM2-independent</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Trigger</td>
<td>Accumulation of Aβ and cellular debris</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>ApoE upregulation, lysosomal genes (Cst7, Cd68)</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Enhanced phagocytosis</td>
</tr>
<tr>
<td class="label">TREM2 Status</td>
<td>TREM2-dependent activation</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Trigger</td>
<td>Chronic neurodegeneration</td>
</tr>
<tr>
<td class="label">Markers</td>
<td>Type II interferon signature, complement proteins</td>
</tr>
<tr>
<td class="label">Function</td>
<td>May become neurotoxic</td>
</tr>
<tr>
<td class="label">TREM2 Status</td>
<td>TREM2-dependent</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>Lipid metabolism, Aβ binding/clearance</td>
</tr>
<tr>
<td class="label">CST7</td>
<td>Lysosomal cysteine protease</td>
</tr>
<tr>
<td class="label">CD68</td>
<td>Phagocytic marker</td>
</tr>
<tr>
<td class="label">TYROBP</td>
<td>TREM2 signaling adaptor</td>
</tr>
<tr>
<td class="label">LPL</td>
<td>Lipoprotein lipase</td>
</tr>
<tr>
<td class="label">CTSB/C</td>
<td>Cathepsins, lysosomal proteases</td>
</tr>
<tr>
<td class="label">AXL</td>
<td>Tyrosine kinase receptor (clearance)</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Function</td>
</tr>
<tr>
<td class="label">P2RY12</td>
<td>Homeostatic microglial marker</td>
</tr>
<tr>
<td class="label">CX3CR1</td>
<td>Fractalkine receptor</td>
</tr>
<tr>
<td class="label">TMEM119</td>
<td>Microglial membrane protein</td>
</tr>
<tr>
<td class="label">SLC2A5</td>
<td>Glucose transporter</td>
</tr>
<tr>
<td class="label">Cytokine/Factor</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Pro-inflammatory, promotes tau pathology</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Acute phase response</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Cytotoxic, promotes neuron loss</td>
</tr>
<tr>
<td class="label">C1q</td>
<td>Complement-mediated synapse elimination</td>
</tr>
<tr>
<td class="label">IL-10</td>
<td>Anti-inflammatory (also upregulated)</td>
</tr>
<tr>
<td class="label">Variant</td>
<td>Effect on DAM</td>
</tr>
<tr>
<td class="label">R47H</td>
<td>~3x AD risk, impaired Aβ phagocytosis</td>
</tr>
<tr>
<td class="label">R62H</td>
<td>Moderate risk, partial impairment</td>
</tr>
<tr>
<td class="label">H157Y</td>
<td>Impaired ligand binding</td>
</tr>
<tr>
<td class="label">T96K</td>
<td>Loss of function</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">TREM2 activation</td>
<td>AGO18, PY314</td>
</tr>
<tr>
<td class="label">CSF1R inhibition</td>
<td>PLX5622 (in mice)</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>TNF inhibitors</td>
</tr>
<tr>
<td class="label">Complement inhibition</td>
<td>C1q, C3 blockers</td>
</tr>
</table>

Disease-associated microglia (DAM) represent a critical innate immune response in the Alzheimer's disease brain. These specialized microglia adopt a distinct transcriptional and functional phenotype in response to neurodegeneration, amyloid pathology, and tau pathology. Understanding DAM biology is essential for developing microglia-targeting therapeutic strategies for AD.

Overview

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: neuron associated cell (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000095)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)
• [OBO Foundry (CL:0000095)](http://purl.obolibrary.org/obo/CL_0000095)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Taxonomy & Classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000095)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000095)
• [OBO Foundry (CL:0000095)](http://purl.obolibrary.org/obo/CL_0000095)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [PanglaoDB](https://panglaodb.se/)

DAM Stages

Disease-associated microglia develop through a staged progression from homeostatic microglia to a fully activated disease-associated phenotype[@kerenshaul2019]:

Stage 1: Early DAM (TREM2-Independent)

Stage 2: Intermediate DAM (TREM2-Dependent)

Stage 3: Fully Activated DAM

Molecular Signature

Upregulated Genes in DAM

Downregulated Genes in DAM

Role in Alzheimer's Disease

Amyloid Clearance

DAM play a complex role in amyloid pathophysiology:

• Protective function: Phagocytic clearance of Aβ plaques
• ApoE-mediated: ApoE4 allele impairs microglial Aβ clearance
• TREM2 variants: R47H (AD risk variant) impairs DAM activation
• Plaque association: DAM cluster around cored plaques

Tau Pathology

Microglia contribute to tau spreading:

• Inflammatory signaling: Cytokines may promote tau phosphorylation
• Neuronal uptake: May facilitate tau internalization
• Spread mechanism: Could transmit tau between neurons
• Neurofibrillary tangles: Associated with more DAM

Neuroinflammation

DAM produce pro-inflammatory mediators:

TREM2 Dependency

TREM2 is critical for DAM activation:

TREM2 Signaling

Aβ/Lipids → TREM2 → TYROBP → SYK → Microglial Activation

AD Risk Variants

Therapeutic Implications

• TREM2 agonists: Small molecules activating TREM2
• TREM2 antibodies: Engineered to promote clustering
• Anti-Aβ antibodies: May enhance microglial clearance
• Gene therapy: TREM2 expression enhancement

DAM in Other Neurodegenerative Diseases

DAM-like phenotypes appear in:

• Parkinson's Disease: α-Synuclein-triggered microglial activation
• ALS: SOD1-triggered neuroinflammation
• FTD: Tau and TDP-43 pathology
• MS: Chronic active lesions
• Huntington's Disease: Mutant HTT-induced activation

Therapeutic Targeting

Current Approaches

Challenges

• Balancing protective vs. harmful functions
• Timing of intervention (early vs. late)
• Peripheral vs. CNS effects
• Biomarker development for DAM activity

See Also

• [/cell-types/disease-associated-microglia-dam — General DAM page](/cell-types/microglia)
• [/proteins/trem2-protein — TREM2 protein](/content/proteins)
• [/proteins/apoe-protein — APOE protein](/content/proteins)
• [/mechanisms/microglia-neuroinflammation — Microglial inflammation](/content/mechanisms)
• [/mechanisms/amyloid-plaque-formation — Amyloid pathology](/content/mechanisms)
• [/diseases/alzheimers-disease — Alzheimer's Disease main page](/content/diseases)

External Links

• [Cell: A Unique Microglial Population (2019)](https://doi.org/10.1016/j.cell.2019.10.037)
• [Nature: TREM2 and DAM (2019)](https://doi.org/10.1038/s41586-019-1768-1)
• [Neuron: Microglia in AD (2020)](https://doi.org/10.1016/j.neuron.2020.02.028)
• [Alzheimer's Association](https://www.alz.org/) — Patient resources
• [NIAAA: TREM2 in AD](https://www.niaaa.nih.gov/) — Research updates

Background

The study of Disease Associated Microglia In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Pathway Diagram

The following diagram shows the key molecular relationships involving Disease-Associated Microglia in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: